These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 26831188

  • 1. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.
    Ponholzer A, Loidl W, Bektic J, Dorfinger K, Hruby S, Jeschke K, Kramer G, Krause S, Ludvik G, Remzi M, Roider M, Stoiber F.
    Wien Klin Wochenschr; 2016 Feb; 128(3-4):156-63. PubMed ID: 26831188
    [Abstract] [Full Text] [Related]

  • 2. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [Abstract] [Full Text] [Related]

  • 3. [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].
    Thomas C, Bögemann M, König F, Machtens S, Schostak M, Steuber T, Heidenreich A.
    Urologe A; 2016 Jun; 55(6):772-82. PubMed ID: 26820660
    [Abstract] [Full Text] [Related]

  • 4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [Abstract] [Full Text] [Related]

  • 5. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 Mar; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 7. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M, Eto M.
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [Abstract] [Full Text] [Related]

  • 8. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 9. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C, Massard C.
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [Abstract] [Full Text] [Related]

  • 10. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F, Fizazi K.
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [Abstract] [Full Text] [Related]

  • 11. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    Virgo KS, Basch E, Loblaw DA, Oliver TK, Rumble RB, Carducci MA, Nordquist L, Taplin ME, Winquist E, Singer EA.
    J Clin Oncol; 2017 Jun 10; 35(17):1952-1964. PubMed ID: 28441112
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 10; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 13. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ, Abiraterone Global EAP Investigators.
    Lancet Oncol; 2014 Oct 10; 15(11):1263-8. PubMed ID: 25242048
    [Abstract] [Full Text] [Related]

  • 14. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].
    Miller K, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, Mickisch G, Pfister D, Schwentner C, Suttmann H, Zastrow S.
    Urologe A; 2016 Sep 10; 55(9):1206-12. PubMed ID: 27411995
    [Abstract] [Full Text] [Related]

  • 15. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
    Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, Altavilla A.
    Expert Rev Anticancer Ther; 2014 Nov 10; 14(11):1283-94. PubMed ID: 25353258
    [Abstract] [Full Text] [Related]

  • 16. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ.
    Eur Urol; 2015 Oct 10; 68(4):570-7. PubMed ID: 25985882
    [Abstract] [Full Text] [Related]

  • 17. Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine.
    Herden J, Heidegger I, Paffenholz P, Porres D.
    Oncol Res Treat; 2015 Oct 10; 38(12):654-68. PubMed ID: 26633646
    [Abstract] [Full Text] [Related]

  • 18. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug 10; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 19. Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review.
    Kretschmer A, Ploussard G, Heidegger I, Tsaur I, Borgmann H, Surcel C, Mathieu R, de Visschere P, Valerio M, van den Bergh RCN, Marra G, Thibault C, Ost P, Gandaglia G, Tilki D, EAU-YAU Prostate Cancer Working Party.
    Eur Urol Focus; 2021 Jul 10; 7(4):742-751. PubMed ID: 32089495
    [Abstract] [Full Text] [Related]

  • 20. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C, Wu TT, Lee HM, Wu HC, Hong SJ, Ou YC, Byun SS, Rhim HY, Kheoh T, Wan Y, Yeh H, Yu MK, Kim CS.
    Int J Urol; 2014 Dec 10; 21(12):1239-44. PubMed ID: 25099185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.